ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

BVXP Bioventix Plc

4,600.00
0.00 (0.00%)
19 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Bioventix Plc LSE:BVXP London Ordinary Share GB00B4QVDF07 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 4,600.00 4,500.00 4,700.00 4,600.00 4,600.00 4,600.00 1,188 08:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Coml Physical, Biologcl Resh 12.82M 8.37M 1.6071 28.62 239.63M

Bioventix Plc Result of AGM

07/12/2016 5:43pm

UK Regulatory


 
TIDMBVXP 
 
Bioventix plc 
 
                        ("Bioventix" or the "Company") 
 
                                 Result of AGM 
 
Bioventix plc (AIM: BVXP) announces that at its Annual General Meeting held 
earlier today, all resolutions put to shareholders were duly passed. 
 
For further information please contact: 
 
Bioventix plc                                     Tel: 01252 728 001 
Peter Harrison           Chief Executive Officer 
 
finnCap Ltd                                       Tel: 020 7220 0500 
Geoff Nash/Simon Hicks   Corporate Finance 
Stephen Norcross         Corporate Broking 
 
About Bioventix plc: 
 
Bioventix (www.bioventix.com) specialises in the development and commercial 
supply of high-affinity monoclonal antibodies with a primary focus on their 
application in clinical diagnostics, such as in automated immunoassays used in 
blood testing. The antibodies created at Bioventix are generated in sheep and 
are of particular benefit where the target is present at low concentration and 
where conventional monoclonal or polyclonal antibodies have failed to produce a 
suitable reagent. Bioventix currently offers a portfolio of antibodies to 
customers for both commercial use and R&D purposes, for the diagnosis or 
monitoring of a broad range of conditions, including heart disease, cancer, 
fertility, thyroid function and drug abuse. Bioventix currently supplies 
antibody products and services to the majority of multinational clinical 
diagnostics companies. Bioventix is based in Farnham, UK and its shares are 
traded on AIM under the symbol BVXP. 
 
 
 
END 
 

(END) Dow Jones Newswires

December 07, 2016 12:43 ET (17:43 GMT)

1 Year Bioventix Chart

1 Year Bioventix Chart

1 Month Bioventix Chart

1 Month Bioventix Chart

Your Recent History

Delayed Upgrade Clock